MINOCA: Diagnostic work-up, risk stratification and tailored therapies.
Myocardial infarction
No obstructive coronary disease
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
25
08
2023
revised:
02
11
2023
accepted:
08
11
2023
pubmed:
17
11
2023
medline:
17
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Myocardial infarction with no obstructive coronary artery disease (MINOCA) diagnostic work-up, risk stratification and tailored therapies are emerging as the recognition of this type of MI is increasingly recognized. Diagnostic workup using advanced imaging can include coronary angiography/intravascular ultrasound (IVUS)/optical coherent tomography (OCT), echo and cardiac magnetic resonance imaging (MRI). Risk stratification portends an intermediate risk compared to multivessel obstructive coronary artery disease (CAD). While event rates are high enough to warrant concern, they are relatively low enough to require trials with large sample sizes and hard outcomes. Tailored therapies include common sense therapeutic lifestyle change (TLC) and optimal medical therapy (OMT) due to the high prevalence of non-obstructive CAD, however therapeutic clinical trials are needed. Currently one large outcome trial in ischemia with no obstructive coronary artery disease (INOCA) is ongoing.
Identifiants
pubmed: 37972700
pii: S1537-1891(23)00103-9
doi: 10.1016/j.vph.2023.107243
pii:
doi:
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
107243Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. C. Noel Bairey Merz, serves as Board of Director for iRhythm, fees paid through CSMC from Abbott Diagnostics and Sanofi. Dr. Janet Wei served on an advisory board for Abbott Vascular. All other authors have nothing to disclose.